Log In
BCIQ
Print this Print this
 

Resiniferatoxin (RTX)

  Manage Alerts
Collapse Summary General Information
Company Sorrento Therapeutics Inc.
DescriptionNon-opiate agonist of the transient receptor potential vanilloid 1 (TRPV1; VR1) receptor
Molecular Target Transient receptor potential vanilloid 1 (TRPV1) (VR1)
Mechanism of ActionTransient receptor potential vanilloid 1 (TRPV1) (VR1) agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationPain
Indication DetailsTreat chronic pain in end-stage cancer patients; Treat severe refractory pain in patients with cancer
Regulatory Designation U.S. - Orphan Drug (Treat chronic pain in end-stage cancer patients)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1.6M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/15/2016

Undisclosed

Undisclosed

Undisclosed

10/21/2013

$1.6M

0

0

Get a free BioCentury trial today